stockrow
Friday 6 November 2026
Export PROF’s income statement to Excel — free account
Profound Medical
PROF Healthcare Medical Devices
Profound Medical’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, up 50.7% from fiscal 2024.
- Revenue
- +85.9%
- EPS
- +18.8%
- Free cash flow
- +47.9%
- Total debt
- +0.71%
Quarter to September 2026, against a year earlier
7.13
0.25
+3.63%
Follow PROF
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 6 | 3 | 3 | 3 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
7.27 | 6.15 | 0.54 | 6.38 | 19.74 | 28.22 | (1.31) | — | — | — |
P/S ratio |
14.78 | 17.42 | 23.39 | 34.45 | 33.44 | 48.68 | 31.43 | 0.00 | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(3.44) | (2.24) | (12.62) | (2.65) | 10.88 | 14.66 | (10.94) | — | — | — |
Beneish M-Score |
(2.62) | (2.80) | (3.17) | (0.29) | (3.46) | (1.47) | — | — | — | — |
P/Operating CF |
(36.24) | (31.64) | (22.98) | (34.78) | (45.48) | (47.75) | (8.69) | 0.00 | 0.00 | — |
P/B ratio |
3.58 | 3.08 | 5.39 | 4.43 | 2.85 | 3.65 | 29.38 | 0.00 | 0.00 | — |
Price to Tangible BV |
3.59 | 3.09 | 5.48 | 4.48 | 3.00 | 3.83 | 0.00 | 0.00 | 0.00 | — |
EV/Sales |
11.63 | 12.71 | 20.74 | 28.56 | 23.87 | 37.43 | 30.05 | 0.00 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.05 | 0.00 | 0.00 | — |
EV/Operating CF |
(4.90) | (5.79) | (6.60) | (7.40) | (7.34) | (13.29) | 0.00 | 0.00 | 0.00 | — |
EV/FCF |
(4.82) | (5.65) | (6.43) | (7.23) | (7.15) | (13.29) | 0.00 | 0.00 | 0.00 | — |
Quick Ratio |
11.02 | 9.44 | 5.26 | 12.63 | 16.50 | 18.99 | 2.20 | 4.30 | 1.45 | 4.26 |
Current Ratio |
12.52 | 10.52 | 6.58 | 14.82 | 18.56 | 20.32 | 2.77 | 4.81 | 1.64 | 4.54 |
Net Debt/EBITDA |
1.36 | 1.56 | 0.69 | 1.29 | 2.32 | 4.75 | 0.42 | 1.00 | 0.36 | 0.89 |
Debt/Assets |
5.81% | 6.64% | 16.16% | 11.14% | 1.58% | 1.61% | 30.39% | 0.00% | 0.00% | 28.64% |
Debt/Equity |
0.07 | 0.08 | 0.23 | 0.14 | 0.02 | 0.02 | 0.64 | 0.45 | 0.37 | 0.46 |
Asset Turnover |
0.22 | 0.19 | 0.13 | 0.09 | 0.07 | 0.11 | 0.18 | 0.00 | 0.45 | 0.00 |
Operating CF/Net income |
0.90 | 0.84 | 0.80 | 0.90 | 0.73 | 0.95 | 0.99 | 0.88 | 0.79 | 0.89 |
Capex/Depreciation |
(0.43) | 0.00 | 0.00 | 0.00 | (0.32) | (0.23) | (0.13) | 0.00 | 0.00 | 0.00 |
Interest Coverage |
— | — | (353.72) | 8.58 | (99.97) | (6.95) | (87.16) | (84.48) | (23.27) | (32.20) |
| (67.12%) | (60.70%) | (68.06%) | (43.23%) | (34.50%) | (38.71%) | (89.68%) | (98.84%) | (135.03%) | (108.45%) | |
| (57.64%) | (48.72%) | (52.27%) | (37.92%) | (32.08%) | (32.11%) | (63.94%) | 0.00% | (171.60%) | (60.69%) | |
ROIC |
(230.01%) | (203.16%) | (147.81%) | (158.59%) | (127.61%) | (77.98%) | (107.00%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(60.20%) | (44.21%) | (77.73%) | (48.81%) | (41.62%) | (23.05%) | (100.75%) | (66.45%) | (218.79%) | (88.33%) |
Average Days of Receivables |
163.25 | 240.77 | 369.51 | 346.59 | 74.99 | 371.35 | 289.45 | 444.08 | 334.27 | 0.00 |
Research and Development Expense of Revenue |
127.94% | 158.85% | 200.36% | 219.88% | 222.28% | 135.71% | 225.13% | 403.70% | 192.08% | 0.00% |
Selling, General and Administrative Expense of Revenue |
199.10% | 216.61% | 257.52% | 268.42% | 261.40% | 170.11% | 189.20% | 413.02% | 178.42% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.01 | 0.01 | 0.05 | 0.04 | 0.17 | 0.00 | 0.00 | 0.01 |
Share Based Compensation of Revenue |
34.10% | 24.17% | 47.46% | 63.43% | 104.83% | 41.32% | 30.33% | 0.00% | 0.00% | — |
Graham Net Nets |
0.27 | 0.32 | 0.17 | 0.22 | 0.31 | 0.25 | 0.05 | 0.00 | 0.00 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(17.92%) | (14.91%) | (16.98%) | (12.49%) | (13.36%) | (5.93%) | (7.49%) | (562.32%) | (536.96%) | — |
Free Cash Flow Yield |
(16.33%) | (12.93%) | (13.78%) | (11.47%) | (9.99%) | (5.79%) | 0.00% | 0.00% | 0.00% | — |
Revenue per Share |
0.53 | 0.43 | 0.34 | 0.32 | 0.34 | 0.42 | 0.38 | 0.19 | 0.64 | 0.00 |
Operating CF per Share |
(1.26) | (0.95) | (1.07) | (1.24) | (1.09) | (1.19) | (1.36) | (1.34) | (1.94) | (2.59) |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | (0.03) | (0.02) | (0.02) | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(1.27) | (0.95) | (1.07) | (1.24) | (1.12) | (1.21) | (1.37) | (1.34) | (1.94) | (2.59) |
Cash per Share |
1.98 | 2.22 | 1.24 | 2.23 | 3.28 | 4.85 | 1.33 | 2.25 | 1.45 | 3.72 |
Shareholders Equity per Share |
2.20 | 2.44 | 1.47 | 2.50 | 3.94 | 5.63 | 1.29 | 1.95 | 1.84 | 2.65 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.20 | 2.44 | 1.47 | 2.50 | 3.94 | 5.63 | 1.29 | 1.95 | 1.84 | 2.65 |
Free Cash Flow |
(38.45) | (23.45) | (22.61) | (25.80) | (22.95) | (20.92) | (15.24) | (13.45) | (11.88) | (10.74) |
Working Capital |
70.01 | 62.50 | 35.53 | 57.84 | 72.97 | 92.93 | 14.58 | 22.09 | 5.50 | 12.99 |
Capital Expenditures |
(0.24) | — | — | — | (0.59) | (0.35) | (0.19) | — | (0.37) | (0.81) |
Net Current Asset Value |
65.05 | 59.25 | 29.16 | 49.61 | 70.97 | 90.49 | 7.12 | 13.23 | 3.09 | 10.09 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 30.05 | 0.00 | 0.00 | — |
Capex to Sales |
0.02 | 0.00 | 0.00 | 0.00 | 0.09 | 0.05 | 0.05 | 0.00 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 31.43 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.80 | 2.20 | 1.02 | 1.78 | 2.38 | 1.79 | 2.87 | 1.39 | 0.51 | 0.20 |
Cash ROIC |
(29.43%) | (19.54%) | (35.03%) | (24.41%) | (15.39%) | (11.44%) | (39.78%) | (26.41%) | (48.73%) | (34.16%) |
Accounts Receivable Turnover |
2.26 | 1.49 | 1.06 | 1.72 | 1.55 | 1.36 | 1.48 | 0.65 | 2.07 | 0.00 |
Accounts Payable Turnover |
3.27 | 3.34 | 1.99 | 1.40 | 1.20 | 1.20 | 0.60 | 0.38 | 1.16 | 0.05 |
Inventory Turnover |
0.67 | 0.57 | 0.39 | 0.48 | 0.62 | 0.85 | 0.56 | 0.69 | 4.29 | 0.19 |
Average Days of Payables |
121.25 | 131.95 | 109.36 | 202.74 | 296.02 | 322.31 | 619.52 | 800.64 | 475.41 | 3,457.55 |
Days of Inventory on Hand |
639.08 | 581.21 | 883.61 | 791.93 | 690.07 | 508.05 | 750.46 | 743.18 | 133.89 | 813.54 |
Average Receivables |
7.12 | 7.17 | 6.82 | 3.88 | 4.42 | 5.37 | 2.82 | 2.96 | 1.89 | 1.89 |
Average Payables |
1.44 | 1.09 | 1.45 | 2.61 | 3.28 | 3.21 | 2.95 | 3.47 | 2.69 | 2.69 |
Average Inventory |
7.02 | 6.40 | 7.47 | 7.68 | 6.37 | 4.50 | 3.17 | 1.91 | 0.73 | 0.73 |
Average Assets |
73.85 | 57.10 | 54.19 | 75.60 | 95.69 | 67.33 | 23.81 | 0.00 | 8.78 | 19.93 |
Average Common Equity |
63.43 | 45.82 | 41.61 | 66.31 | 88.98 | 55.86 | 16.97 | 15.45 | 11.15 | 11.15 |
Columns are period end dates · fundamentals updated 5 Nov 2026